Elite Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.20 M
as on 01-01-2025
- Paid Up Capital ₹ 1.10 M
as on 01-01-2025
- Company Age 37 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.25 Cr
as on 01-01-2025
- Revenue 0.21%
(FY 2022)
- Profit -13.74%
(FY 2022)
- Ebitda -36.06%
(FY 2022)
- Net Worth 10.96%
(FY 2022)
- Total Assets 7.72%
(FY 2022)
About Elite Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.20 M and a paid-up capital of Rs 1.10 M.
The company has closed loans amounting to ₹1.25 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Girish Kantaria, Popatlal Patel, and Chintan Patel serve as directors at the Company.
- CIN/LLPIN
U24231GJ1987PTC010062
- Company No.
010062
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Oct 1987
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Elite Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Girish Kantaria  | Director | 16-Oct-1987 | Current |
| Popatlal Patel | Director | 16-Oct-1987 | Current |
| Chintan Patel | Director | 28-Apr-2017 | Current |
Financial Performance of Elite Pharma.
Elite Pharma Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 0.21% increase. The company also saw a substantial fall in profitability, with a 13.74% decrease in profit. The company's net worth Soared by an impressive increase of 10.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elite Pharma?
Unlock access to Elite Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 17 Jun 2005 | ₹3.70 M | Satisfied |
Bank Of India Creation Date: 27 Dec 2003 | ₹6.19 M | Satisfied |
Bank Of India Creation Date: 05 Feb 1996 | ₹0.20 M | Satisfied |
How Many Employees Work at Elite Pharma?
Elite Pharma has a workforce of 7 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elite Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elite Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
